Employees Retirement System of Texas Purchases Shares of 78,950 Genmab A/S (NASDAQ:GMAB)

Employees Retirement System of Texas acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 78,950 shares of the company's stock, valued at approximately $16,477,000.

Other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC raised its stake in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its holdings in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after acquiring an additional 950 shares during the period. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the last quarter. Cromwell Holdings LLC lifted its position in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after acquiring an additional 2,496 shares during the period. Finally, R Squared Ltd acquired a new position in Genmab A/S in the 4th quarter valued at $93,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Up 4.4 %

Shares of GMAB stock traded up $0.80 during mid-day trading on Friday, hitting $18.81. 1,524,787 shares of the company's stock were exchanged, compared to its average volume of 1,018,227. The stock has a market cap of $12.45 billion, a price-to-earnings ratio of 10.81, a PEG ratio of 2.65 and a beta of 1.07. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.41. The stock has a 50-day simple moving average of $20.48 and a two-hundred day simple moving average of $21.31.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GMAB. HC Wainwright reissued a "buy" rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research note on Wednesday. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Finally, Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.